Oxford BioDynamics Plc (LON:OBD – Get Free Report)’s share price hit a new 52-week low during trading on Monday . The company traded as low as GBX 0.37 ($0.00) and last traded at GBX 0.39 ($0.01), with a volume of 8083034 shares traded. The stock had previously closed at GBX 0.43 ($0.01).
Analysts Set New Price Targets
Separately, Shore Capital reissued a “house stock” rating on shares of Oxford BioDynamics in a research note on Thursday, March 13th.
Oxford BioDynamics Stock Performance
Oxford BioDynamics (LON:OBD – Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.
Oxford BioDynamics Company Profile
Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
See Also
- Five stocks we like better than Oxford BioDynamics
- Best Stocks Under $5.00
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- 3 Best Fintech Stocks for a Portfolio Boost
- Are Tariffs Threatening Disney’s Comeback Story?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.